Oncology Times

Lymphoma & Leukemia Resource Center Blog

    Specified user is not valid
      • The Evolving Treatment of Chronic Lymphocytic Leukemia

        Published Jan 31 2019, 12:06 PM by Caitlin Coles

        Over the past 5 years, the field of chronic lymphocytic leukemia (CLL) has seen the emergence of multiple new classes of therapies, including Bruton’s tyrosine kinase (BTK) inhibitors, phosphatidylinositol-3-kinase (PI3K) inhibitors, and BCL-2 inhibitors. These therapies have revolutionized treatment of the disease, but we still have much to learn about their long-term safety and efficacy, the ways they can be combined, and the ways they can be improved. In this blog post, we provide an overview of some recent research that falls into each of these three areas.

      • Advances in Follicular Lymphoma Management

        Published Jul 03 2018, 03:13 PM by Caitlin Coles

        Follicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma (NHL) and the most common indolent NHL, accounts for 35 percent of NHLs in the U.S. FL arises from germinal center B cells, which are usually CD10 positive, CD5 negative, and CD20 and CD19 positive.

      • Evolving Role of Chemotherapy in the Management of CLL

        Published May 15 2018, 03:44 PM by Caitlin Coles

        Chemotherapy and more specifically chemoimmunotherapy has been standard treatment for patients with CLL. Commonly used regimens are FCR (fludarabine, cyclophosphamide, rituximab), BR (bendamustine, rituximab), and chlorambucil plus obinutuzumab.